---
title: ""
page-layout: full
title-block-banner: false
include-in-header: 
  - text: |
      <style>
        body {
          background: url('files/soco_jc_hero1.png') center center / cover no-repeat fixed;
          background-color: #000; /* fallback */
          color: white; /* if needed, based on contrast */
          text-align: justify;
        }
        h1.title {
          text-align: center;
          padding-top: 120px;
        }

        /* Make plot outputs fill more width */
        .cell-output-display {
          max-width: 100% !important;
        }

        /* Optionally remove left/right padding */
        main.content {
          padding-left: 2rem;
          padding-right: 2rem;
        }
        .hero-title-container {
          text-align: center;
          padding: 5rem 2rem 3rem 2rem;
          background: linear-gradient(to bottom, rgba(0,0,0,0.75), rgba(0,0,0,0.3));
          color: white;
          max-width: 100%;
        }
        
        .hero-title-container h1 {
          font-family: 'Playfair Display', serif;
          font-size: clamp(1.6rem, 2.8vw, 2.25rem);
          line-height: 1.5;
          font-weight: 700;
          margin: 0 auto;
          max-width: 1000px;
          text-shadow: 0 2px 4px rgba(0,0,0,0.5);
        }
        .hero-title-box {
          background: none;
          color: black;
          padding: 2rem 2rem 0 2rem;
          margin: 0 auto;
          text-align: center;
          font-family: 'Playfair Display', serif;
          font-size: clamp(1.5rem, 2.2vw, 2.25rem);
          font-weight: 700;
          line-height: 1.4;
          max-width: min(95vw, 1200px);
          margin-top: 4rem;
        }
      
      </style>
format: html
toc: false
listing: 
  - id: content
    contents:
      - article/Introduction
      - article/Table_1
      - article/Table_2
      - article/Table_3
      - article/Figure_1
      - article/Figure_2a
      - article/Figure_2b
      - article/Table_4
    type: default
    sort: "none"
---

<div class="hero-title-box">
  Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma:<br><br>
  A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
</div>



<div class="fade-in" id="overview">
## Introduction
<div class="fade-in">
:::{#Introduction}
:::
</div>

</div>

<div class="fade-in" id="overview">
## Tables and Figures
<div class="fade-in">
:::{#Table_1}
:::
</div>

<div class="fade-in">
:::{#Table_2}
:::
</div>

<div class="fade-in">
:::{#Table_3}
:::
</div>

<div class="fade-in">
:::{#Figure_1}
:::
</div>

<div class="fade-in">
:::{#Figure_2a}
:::
</div>

<div class="fade-in">
:::{#Figure_2b}
:::
</div>

<div class="fade-in">
:::{#Table_4}
:::
</div>
</div>